Want to see EVMN full AI Analyst Report?
Top Page
Evommune, Inc.
(NYSE:EVMN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$9.50
▼(-22.58% Downside)
Action:Reiterated
Date:09/24/26
The score is primarily held down by weak financial performance (large ongoing net losses and accelerating cash burn) and bearish technicals (price well below major moving averages with negative MACD). A strengthened 2025 balance sheet and mixed-but-partly positive pipeline developments (notably EVO301 AD data visibility) provide some support, but not enough to outweigh profitability and momentum concerns.
Positive Factors
Revenue Growth
Revenue has more than doubled since 2023, showing improving commercial or partnership-related inflows despite the company’s clinical-stage profile. If this trajectory continues, greater scale could help absorb fixed research costs and gradually improve operating leverage over the next several quarters.
Negative Factors
Escalating Cash Burn
Cash outflows are deep and worsening, meaning current operations do not fund development and the company remains dependent on financing or faster revenue growth. Persistent burn can constrain trial execution, reduce strategic flexibility, and create funding pressure before programs reach commercial scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue has more than doubled since 2023, showing improving commercial or partnership-related inflows despite the company’s clinical-stage profile. If this trajectory continues, greater scale could help absorb fixed research costs and gradually improve operating leverage over the next several quarters.
Read all positive factors
Evommune, Inc. (EVMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$308.12M
Dividend YieldN/A
Average Volume (3M)628.18K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees48
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding36,292,114
10 Day Avg. Volume692,229
30 Day Avg. Volume628,185
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.00Price Target Upside95.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$3.13M
Evommune, Inc. Business Overview & Revenue Model
Company Description
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical de...
Evommune, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 10.00M | 13.00M | 7.00M | 5.00M |
| Gross Profit | 9.65M | 13.00M | 5.71M | 4.00M |
| EBITDA | -95.78M | -67.48M | -65.49M | -32.99M |
| Net Income | -94.67M | -68.87M | -66.81M | -34.05M |
Balance Sheet | ||||
| Total Assets | 301.95M | 224.95M | 76.06M | 82.25M |
| Cash, Cash Equivalents and Short-Term Investments | 200.79M | 149.20M | 72.04M | 79.08M |
| Total Debt | 8.11M | 2.06M | 193.31M | 150.63M |
| Total Liabilities | 24.36M | 19.38M | 220.29M | 159.96M |
| Stockholders Equity | 277.59M | 205.57M | -144.24M | -77.71M |
Cash Flow | ||||
| Free Cash Flow | -74.65M | -76.68M | -58.28M | -30.09M |
| Operating Cash Flow | -74.15M | -76.44M | -58.20M | -29.97M |
| Investing Cash Flow | -200.87M | -115.31M | -3.99M | -48.43M |
| Financing Cash Flow | 274.22M | 220.76M | 49.42M | 63.75M |
Evommune, Inc. Technical Analysis
Negative
12.27
Price Trends
11.98
Negative
15.75
Negative
19.16
Negative
Market Momentum
-1.20
Positive
25.68
Positive
16.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVMN, the sentiment is Negative. The current price of 12.27 is above the 20-day moving average (MA) of 10.46, above the 50-day MA of 11.98, and below the 200-day MA of 19.16, indicating a bearish trend. The MACD of -1.20 indicates Positive momentum. The RSI at 25.68 is Positive, neither overbought nor oversold. The STOCH value of 16.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVMN.
Evommune, Inc. Risk Analysis
Evommune, Inc. disclosed 78 risk factors in its most recent earnings report. Evommune, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our use and provision of AI-powered solutions could lead to operational or reputational damage, competitive harm, legal and regulatory risk and additional costs. Q2, 2026
Evommune, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $1.80B | -5.68 | -29.99% | ― | 1495.93% | 53.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $393.66M | -4.34 | -46.54% | 1.29% | -82.95% | -49.04% | |
52 Neutral | $595.22M | -3.79 | -31.41% | 1310.82% | 55.00% | 33.01% | |
49 Neutral | $573.44M | -3.08 | -152.15% | ― | -21.91% | -134.63% | |
48 Neutral | $345.89M | -4.08 | 1688.22% | ― | -3.66% | -28.98% | |
46 Neutral | $308.12M | -2.96 | -62.63% | ― | ― | ― |
* General Sector Average
EVMN
Evommune, Inc.
8.39
-11.84
-58.53%
ALT
Altimmune
2.96
-0.83
-21.90%
ARCT
Arcturus Therapeutics
14.46
-4.32
-23.00%
OCGN
Ocugen
1.03
-0.42
-28.97%
VIR
Vir Biotechnology
10.51
4.88
86.68%
VALN
Valneva
6.47
-4.48
-40.91%
Evommune, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
Positive
Sep 23, 2026
Evommune, Inc., a clinical-stage biotech developer of therapies for chronic inflammatory diseases, is advancing EVO301, a long-acting IL-18 binding protein fusion designed to neutralize aberrant IL-18 activity across multiple inflammatory pathways...
Business Operations and StrategyProduct-Related Announcements
Evommune updates pipeline and market outlook in presentation
Positive
Sep 15, 2026
On September 15, 2026, Evommune, Inc. posted an updated corporate presentation outlining progress across its pipeline of inflammatory disease therapies and the scale of its target markets. The deck emphasizes EVO301’s potential as a foundati...
Business Operations and StrategyProduct-Related Announcements
Evommune Shifts Atopic Dermatitis Focus to EVO301
Negative
Sep 9, 2026
On September 8, 2026, Evommune reported top-line data from a randomized, double-blind, placebo-controlled Phase 2b trial of its oral MRGPRX2 antagonist EVO756 in 121 adults with moderate-to-severe atopic dermatitis. The 12-week study, with follow-...
Business Operations and StrategyProduct-Related Announcements
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
Positive
Jul 30, 2026
On July 30, 2026, Evommune announced that it had dosed the first patient in a global Phase 2b clinical trial of its oral MRGPRX2 inhibitor, EVO756, for prophylactic treatment of refractory migraine. The randomized, double-blind, placebo-controlled...
Business Operations and StrategyProduct-Related Announcements
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
Negative
Jun 29, 2026
On June 29, 2026, Evommune reported top-line results from a randomized, double-blind, placebo-controlled Phase 2b trial of oral MRGPRX2 antagonist EVO756 in 160 adults with moderate-to-severe, antihistamine-refractory chronic spontaneous urticaria...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.